A Phase III Study of Double Autotransplantation Incorporating Bortezomib-Thalidomide-Dexamethasone (VTD) or Thalidomide-Dexamethasone (TD) for Multiple Myeloma: Superior Clinical Outcomes with VTD Compared to TD

被引：0
|
作者：
Cavo, Michele [1 ]
Tacchetti, Paola [1 ]
Patriarca, Francesca
Petrucci, Maria Teresa
Pantani, Lucia [1 ]
Galli, Monica
Di Raimondo, Francesco
Crippa, Claudia
Bringhen, Sara
Offidani, Massimo
Narni, Franco
Montefusco, Vittorio
Zamagni, Elena [1 ]
Spadano, Tonino
Pescosta, Norbert
Baldini, Luca
Cellini, Claudia
Caravita, Tommaso
Ledda, Antonio
Falcone, Antonietta
Tosi, Patrizia [1 ]
Nozzoli, Chiara
Zambello, Renato
Masini, Luciano
Agostini, Paola
Fiacchini, Mauro [1 ]
Baccarani, Michele [1 ]
机构：
[1] Univ Bologna, Sch Med, Seragnoli Inst Hematol, Bologna, Italy
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：148 / 149
页数：2
相关论文
共 50 条
  • [1] Bortezomib(Velcade®)-Thalidomide-Dexamethasone (VTD) Is Superior to Thalidomide-Dexamethasone (TD) In Patients with Multiple Myeloma (MM) Progressing or Relapsing After Autologous Transplantation.
    Garderet, Laurent
    Iacobelli, Simona
    Moreau, Philippe
    Dib, Mamoun
    Caillot, Denis
    Niederwieser, Dietger W.
    Masszi, Tamas
    Fontan, Jean
    Michallet, Mauricette
    Gratwohl, Alois
    Milone, Giuseppe
    Doyen, Chantal
    Pegourie, Brigitte
    Hajek, Roman
    Casassus, Philippe
    Kolb, Brigitte
    Chaleteix, Carine
    Hertenstein, Bernd
    Onida, Francesco
    Ludwig, Heinz
    Vekemans, Marie Christiane
    Ketterer, Nicolas
    Daguenel, Anne
    Gorin, Norbert C.
    Harousseau, Jean Luc
    de Witte, Theo
    Morris, Curly
    Gahrton, Gosta
    [J]. BLOOD, 2010, 116 (21) : 1254 - 1254
  • [2] Thalidomide/Dexamethasone (TD) Versus Bortezomib (Velcade)/Thalidomide/Dexamethasone (VTD) Versus VB
    Rosinol, L.
    Cibeira, M. T.
    Martinez, J.
    Mateos, M. V.
    Terol, M. J.
    de la Rubia, J.
    Palomera, L.
    de Arriba, F.
    Oriol, A.
    Amor, A. A.
    Besalduch, J.
    de Paz, R.
    Garcia-Larana, J.
    Diaz-Mediavilla, J.
    Sureda, A.
    Lahuerta, J. J.
    San Miguel, J.
    Blade, J.
    [J]. CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S26 - S26
  • [3] Bortezomib (BOR)-Thalidomide-Dexamethasone (VTD) as induction treatment for newly diagnosed Multiple Myeloma (MM) is associated with a lower rate of Second Primary Malignancies (SPMs) compared to Thalidomide-Dexamethasone (TD)
    Brioli, A.
    Pezzi, A.
    Muegge, L-O
    Derudas, D.
    Petti, M. C.
    Zannetti, B. A.
    Ferrara, F.
    Rocchi, S.
    Nobile, F.
    Baraldi, A.
    Musto, P.
    Lanza, F.
    Mancuso, K.
    Canepa, L.
    Catalano, L.
    Lazzaro, A.
    Pinotti, G.
    Boccadoro, M.
    Hochhaus, A.
    Cavo, M.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 69 - 69
  • [4] Bortezomib- and Thalidomide-Induced Peripheral Neuropathy (PN) in Multiple Myeloma (MM): Clinical and Molecular Analysis of 474 Patients Treated with Thalidomide-Dexamethasone (TD) or Bortezomib-TD (VTD)
    Tacchetti, Paola
    Terragna, Carolina
    Catania, Gioacchino
    Marcatti, Magda
    Nozza, Andrea
    Ferrara, Felicetto
    Nobile, Francesco
    Califano, Catello
    Baraldi, Anna
    Gallamini, Andrea
    Musto, Pellegrino
    Tosi, Patrizia
    Galieni, Piero
    Pezzi, Annalisa
    Lanza, Francesco
    Ceccolini, Michela
    Ballerini, Filippo
    Catalano, Lucio
    Cangialosi, Clotilde
    Lazzaro, Antonio
    Paladini, Giorgio
    Mozzana, Ruggero
    Zannetti, Beatrice Anna
    Pinotti, Graziella
    Elice, Francesca
    Baccarani, Michele
    Boccadoro, Mario
    Cavaletti, Guido
    Cavo, Michele
    [J]. BLOOD, 2011, 118 (21) : 794 - 795
  • [5] Bortezomib-Thalidomide-Dexamethasone Incorporated Into Autotransplantation Is Associated with More Favorable Outcomes After Relapse in Comparison with Thalidomide-Dexamethasone Plus Autotransplantation in Multiple Myeloma
    Cavo, Michele
    Galli, Monica
    Pantani, Lucia
    Di Raimondo, Francesco
    Crippa, Claudia
    Offidani, Massimo
    Zamagni, Elena
    Montefusco, Vittorio
    Narni, Franco
    Pezzi, Annalisa
    Spadano, Antonio
    Pescosta, Norbert
    Tacchetti, Paola
    Baldini, Luca
    Ledda, Antonio
    Cellini, Claudia
    Caravita, Tommaso
    Falcone, Antonietta
    Nozzoli, Chiara
    Zambello, Renato
    Masini, Luciano
    Boccadoro, Mario
    [J]. BLOOD, 2012, 120 (21)
  • [6] Bortezomib (velcade(R))-thalidomide-dexamethasone (VTD) vs thalidomide-dexamethasone (TD) in preparation for autologous stem-cell (SC) transplantation (ASCT) in newly diagnosed multiple myeloma (MM)
    Cavo, Michele
    Patriarca, Francesca
    Tacchetti, Paola
    Galli, Monica
    Perrone, Giulia
    Petrucci, Maria Teresa
    Brioli, Annamaria
    Bringhen, Sara
    Pantani, Lucia
    Tosi, Patrizia
    Crippa, Claudia
    Zamagni, Elena
    Di Raimondo, Francesco
    Narni, Franco
    Cellini, Claudia
    Ceecolini, Michela
    Pescosta, Norbert
    Goldaniga, Maria Cecilia
    Montefusco, Vittorio
    Callea, Vincenzo
    De Stefano, Valerio
    Caravita, Tommaso
    Boccadoro, Mario
    Baccarani, Michele
    [J]. BLOOD, 2007, 110 (11) : 30A - 30A
  • [7] VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma
    Pineda-Roman, M.
    Zangari, M.
    van Rhee, F.
    Anaissie, E.
    Szymonifka, J.
    Hoering, A.
    Petty, N.
    Crowley, J.
    Shaughnessy, J.
    Epstein, J.
    Barlogie, B.
    [J]. LEUKEMIA, 2008, 22 (07) : 1419 - 1427
  • [8] Retrospective comparison of transplant outcomes in patients with multiple myeloma according to induction therapy with thalidomide/dexamethasone (TD) with or without bortezomib (VTD)
    Giralt, Sergio
    Thandi, Rupi
    Qazilbash, Muzaffar
    Mendoza, Floralyn
    Han, Eric
    Hosing, Chitra
    Wang, Michael
    Thomas, Sheeba
    Alexanian, Raymond
    Champlin, Richard
    Weber, Donna
    [J]. BLOOD, 2007, 110 (11) : 288A - 288A
  • [9] IMPACT OF CONSOLIDATION WITH BORTEZOMIB-THALIDOMIDE-DEXAMETHASONE (VTD) UPFRONT IN MULTIPLE MYELOMA (MM) WITH PARTIAL RESPONSE (PR) AT COMPLETION OF INDUCTION WITH VTD
    Fouquet, G.
    Hebraud, B.
    Garciaz, S.
    Stoppa, A. M.
    Roussel, M.
    Caillot, D.
    Chretien, M. L.
    Arnulf, B.
    Szalat, R.
    Garderet, L.
    Benajiba, L.
    Pegourie, B.
    Regny, C.
    Royer, B.
    Caulier, A.
    Touzeau, C.
    Tessoulin, B.
    Fermand, J. P.
    Facon, T.
    Attal, M.
    Avet-Loiseau, H.
    Moreau, P.
    Leleu, X.
    [J]. HAEMATOLOGICA, 2014, 99 : 367 - 367
  • [10] Superior Complete Response Rate (CR) and Progression-Free Survival (PFS) with Bortezomib-Thalidomide-Dexamethasone (VTD) Versus Thalidomide-Dexamethasone (TD) As Consolidation Therapy After Autologous Stem-Cell Transplantation (ASCT) in Multiple Myeloma (MM)
    Cavo, Michele
    Pantani, Lucia
    Patriarca, Francesca
    Petrucci, Maria Teresa
    Galli, Monica
    Di Raimondo, Francesco
    Rossi, Giuseppe
    Palumbo, Antonio
    Tacchetti, Paola
    Offidani, Massimo
    Montefusco, Vittorio
    Narni, Franco
    Spadano, Tonino
    Cellini, Claudia
    Pescosta, Norbert
    Baldini, Luca
    Ledda, Antonio
    Di Toritto, Tommaso Caravita
    Pezzi, Annalisa
    Falcone, Antonietta
    Nozzoli, Chiara
    Zambello, Renato
    Masini, Luciano
    Gherlinzoni, Filippo
    Petti, Maria Concetta
    Derudas, Daniele
    Ballanti, Stelvio
    De Stefano, Valerio
    Baccarani, Michele
    [J]. BLOOD, 2011, 118 (21) : 816 - 816
12345